Facebook
Twitter
LinkedIn
Forward
Targeting DED: Aiming Treatments at Optimal Results (CE Webcast)
Activity Description and Purpose
Dry eye disease (DED) is a prevalent and multifactorial condition that significantly impacts patients’ quality of life. This webcast aims to provide optometrists with comprehensive strategies to diagnose and manage DED effectively. The program will cover the latest advancements in diagnostic tools and treatment options, emphasizing the importance of personalized and targeted therapeutic approaches. Optometrists will gain insights into the pathophysiologic mechanisms underlying DED, including tear film instability, meibomian gland dysfunction, and the role of inflammation. Through case presentations and expert discussions, optometrists will learn to design and implement evidence-based treatment plans tailored to individual patient needs, ultimately improving clinical outcomes and patient satisfaction.
Target Audience
This educational activity is intended for optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Incorporate diagnostic strategies for DED into practice
- Review the pathophysiologic factors of DED
- Design evidence-based treatment plans for patients with DED
Faculty
 | Kelly K. Nichols, OD, MPH, PhD, FAAO (Chair) |
 | Selina McGee, OD, FAAO |
 | Justin A. Schweitzer, OD, FAAO |
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any ineligible company. Financial relationship information is collected and resolved prior to the educational activity.
Faculty
Selina McGee, OD, FAAO, is a consultant for AbbVie Inc, Aldeyra Therapeutics, Amgen Inc, Avellino, Bruder Healthcare, Cynosure, Dompé US, Inc, Eyevance, Harrow, Inc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, Optovue, Oyster Point Pharma, Inc, RVL Pharmaceuticals, Inc, ScienceBased Health, Sun Pharmaceutical Industries Ltd, Tarsus Pharmaceuticals, Inc, Thea Pharma Inc, Topcon Medical Systems, Inc, Trukera, and Versant Ventures; and is on the speakers bureau for AbbVie Inc, Bausch & Lomb Incorporated, Cynosure, Dompé US, Inc, Lumenis, Optovue, Oyster Point Pharma, Inc, and Tarsus Pharmaceuticals, Inc.
Kelly K. Nichols, OD, MPH, PhD, FAAO, is a consultant for AbbVie Inc, Alcon, Aldeyra Therapeutics*, Azura Ophthalmics, Bausch & Lomb Incorporated, Bruder Healthcare, Cavalry Biosciences, Dompé US, Inc, HanAll Biopharma*, Harrow, Inc, Nicox*, Novaliq GmbH, Novartis Pharmaceuticals Corporation, Osmotica Pharmaceuticals plc*, Oyster Point Pharma, Inc, Palatin Technologies, Inc*, RVL Pharmaceuticals, Inc*, Sight Sciences, Takeda Pharmaceuticals USA, Inc, Tarsus Pharmaceuticals, Inc, TearSolutions, Thea Pharma Inc, Topcon Medical Systems, Inc, TopiVert Ltd*, Trukera, Verséa Health, Inc, and Xequel Bio*; is on the speakers bureau for Bausch & Lomb Incorporated*; is a contracted researcher for Aramis Biosciences, KOWA Pharmaceuticals America, Inc, ScienceBased Health, Sylentis, and TearScience; and is a stockholder or has stock options in Axim Biotechnologies Inc* and Oyster Point Pharma, Inc*.
Justin A. Schweitzer, OD, FAAO, is a consultant for AbbVie Inc, Aerie Pharmaceuticals, Inc, Alcon, Astellas Pharma Inc, Avellino, Bausch & Lomb Incorporated, Dompé US, Inc, EyePoint Pharmaceuticals, Glaukos Corporation, Kala Pharmaceuticals, LKC Technologies, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Quidel Corporation, Reichert, Inc, RVL Pharmaceuticals, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, Visus Therapeutics, and Zeiss; is on the speakers bureau for AbbVie Inc, Aerie Pharmaceuticals, Inc, Alcon, Bausch & Lomb Incorporated, Glaukos Corporation, LKC Technologies, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, and Zeiss; and is on the advisory board of AbbVie Inc, Aerie Pharmaceuticals, Inc, Alcon, Astellas Pharma Inc, Avellino, Bausch & Lomb Incorporated, Dompé US, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, RVL Pharmaceuticals, Inc, ScienceBased Health, Sight Sciences, Visus Therapeutics, and Zeiss.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant financial relationships with ineligible companies to disclose.
* The financial relationship existed during the past 24 months but has now ended
Accreditation Statement
COPE approved for 1.5 CE credits for optometrists.
COPE Course ID: 95447-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease
Administrator: 
This activity, COPE Activity Number 129842, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus LLC has received commercial support from Bausch & Lomb Incorporated for this activity in the form of an unrestricted educational grant.
The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Sponsored by 
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at [email protected].
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of State University of New York College of Optometry, MedEdicus LLC, or Bausch & Lomb Incorporated.
This CE activity is copyrighted to MedEdicus LLC ©2025. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 319.4b
Available Credit
- 1.50 COPE